Tony Reid

Company: EpicentRx

Job title: Chief Executive Officer

Seminars:

Exploring the Development of RRx-001: the NLRP3 Small Molecule Inhibitor for a Variety of Inflammatory Diseases 9:30 am

Understanding the mechanism of action and preclinical data for the therapeutic candidate Highlighting key formulation and delivery considerations to be on-target and measuring off-target effects Identifying the next steps for the therapeutic candidateRead more

day: Conf Day 2